SKINNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
SkinHealth Systems Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.55−0.01 (-0.09%)
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
65.3%+8.9 pts over 5 years
Operating margin
-6.9%+7.5 pts over 5 years
Net margin
-3.2%+21.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -10.0% | -6.3% | +20.4% | – | |
| Gross profit | +7.7% | -7.6% | +23.9% | – | |
| Free cash flow | +141.8% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 183.6% | -16.9% | |
| Return on assets | – | – | -1.6% | |
| Current ratio | – | 1.91 | 1.66 | |
| Interest coverage | – | – | -1.1× | |
| Inventory turnover | – | – | 1.8× | |
| Capex to revenue | – | 2.9% | 0.1% | |
| Diluted shares | – | 34M | 136M |
Where the cash went
Fiscal 2021 to 2025, five years combined
SkinHealth Systems generated $210.33M from operations and spent $217.09M on capital expenditure, dividends and share buybacks. 12% of that went back into the business.
Generated
$210.33M
Used
$217.09M
Capital expenditure$26.93M12%Dividends$00%Share buybacks$190.16M88%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.2%
×Asset turnover0.51×
×Equity multiplier10.50×
=Return on equity, FY2025-16.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3.2% | 0.51× | 10.50× | -16.9% |
| FY2024 | -8.7% | 0.41× | 14.52× | -52.3% |
| FY2023 | -25.2% | 0.41× | 8.53× | -88.4% |
| FY2022 | 12.1% | 0.33× | 4.78× | 19.0% |
| FY2021 | -145.6% | 0.36× | 5.39× | -283.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$9.52M
- Cash generatingOperating cash flow above zero$37.49M
- Return on assets improvedROA up on the prior year-3.1% → -1.4%
- Earnings backed by cashOperating cash flow above net income$37.49M vs -$9.52M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.00 → 1.66
- No dilutionShare count did not rise142M → 136M
- Gross margin improvedGross margin up on the prior year54.53% → 65.28%
- More efficientAsset turnover rose0.36 → 0.44